TLDR New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
The document discusses the challenges of diagnosing and treating hair loss, or alopecia, and highlights recent advances in the field. It emphasizes the importance of educating dermatologists and primary care providers on identifying and distinguishing between different types of hair loss, and how to manage them. The document mentions the approval of baricitinib, a Janus kinase inhibitor, for alopecia areata by the FDA in 2022, which has increased awareness of the disease. Other Janus kinase inhibitors are also in phase 3 trials. The document also discusses the use of low-dose oral minoxidil for androgenetic alopecia, which has gained popularity since its first use in 2018 due to its tolerability and minimal side effects. The document concludes by emphasizing the importance of patient counseling in managing alopecia, and the need for dermatologists to develop a tiered approach to treating patients with alopecia.
Cited in this study
6 / 6 results
39 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil safely treats hair loss, with hypertrichosis as main side effect.
7 citations
,
April 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil may cause side effects like hypertrichosis and is not suitable for everyone.
59 citations
,
March 2021 in “Journal of The American Academy of Dermatology” Oral minoxidil promotes hair growth but may cause side effects; needs monitoring.
14 citations
,
September 2020 in “Dermatologic Therapy” Low-dose oral minoxidil is a safe treatment for hair loss, with the main side effect being excessive hair growth. Other side effects like foot swelling, low blood pressure when standing, and heart rate changes are rare.
80 citations
,
January 2018 in “International Journal of Dermatology” Low-dose oral minoxidil and spironolactone combo effectively reduces hair loss and improves hair density in women.
185 citations
,
December 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
January 2022 in “Elsevier eBooks” The document's conclusion cannot be summarized because it is not readable or understandable.
August 2021 in “Pharmacy Today” The document's conclusion about hair loss cannot be determined.
2 citations
,
December 2018 in “Seminars in Cutaneous Medicine and Surgery”
January 2016 The article concludes that understanding the causes of hair loss and using continuous treatments like minoxidil and finasteride can help manage it, despite potential side effects.
January 2015 in “Rawal Medical Journal”
August 2013 in “Pharmacy Today” Viviscal may modestly improve hair loss in women without adverse effects.
54 citations
,
January 2013 in “Dermatologic Clinics” Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.
86 citations
,
July 2002 in “Clinical and Experimental Dermatology” FPHL is a common, age-related, genetic hair loss with unclear causes and limited treatment options.